Abbott’s Tendyne Receives CE Mark as the World’s First Transcatheter Mitral Valve Implantation System in Europe

Abbott's Tendyne Receives CE Mark as the World's First Transcatheter Mitral Valve Implantation System in Europe

Shots:

  • Abbott’s Tendyne TMVI system received CE Mark to treat MR in patients requiring a heart valve replacement and is a safe and effective solution for patients who are not candidates for open-heart surgery or transcatheter mitral valve repair
  • The approval in the EU allows HCPs to completely treat MR and expands Abbott’s portfolio of innovative minimally invasive mitral valve solutions
  • Abbott’s Tendyne valve is a first-of-its-kind therapy to replace the mitral valve, without open surgery and when a transcatheter mitral repair is not possible. Tendyne valve provides relief from HF symptoms and improves QoL in high-surgical-risk patients

Click here to­ read full press release/ article | Ref: Abbott | Image: Star Tribune